By proceeding, you agree to our Terms of Use and Privacy Policy.
24-24 January 2023
Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. Recombinant proteins and monoclonal antibo
Event Ended
Virtual
Free
21-23 February 2023
From A-Z of phage development, the 5th Bacteriophage Therapy Summit is the definitive commercial-orientated conference to accelerate phage-based applications for organizations pioneering with phage pipelines.
Paid
31 January-02 February 2023
From hypothetical to reality, the first ever approval of a microbiome-based therapy is here and is set to propel the industry forward, expanding across a wide range of diseases.
UK
London
The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field.
USA
Boston
07-09 March 2023
The surge of clinical approvals in CKD and unprecedented use of surrogate endpoints in rare kidney diseases have catalysed a new era of complimentary therapies and precision medicine in drug development for kidney disease.
14-15 March 2023
The Advanced Therapies Congress is Europe’s largest cell and gene therapy conference and exhibition. The event is for the leaders of the world’s ATMP developers and their most senior executives in charge of the latest tech and strategies that are dri
02-03 March 2023
NASH continues to be a huge unmet clinical need globally, and although no therapy has received regulatory approval, there continues to be research advancing our understanding of the disease’s mechanisms.
Hybrid
30 January-01 February 2023
The Precision Medicine in Inflammatory Bowel Disease Summit aims to address the urgent need for personalized care for the 10 million people worldwide living with IBD. The current one-size-fits-all approach to treatment is not effective, and precision
24-26 January 2023
Welcome to the 2nd HFpEF & HCM Drug Discovery & Development Summit The Industry's Only Definitive Forum for Cardiovascular Drug Discovery & Development Cardiovascular stakeholders are racing to answer the burning questions limiting them from capitali
20-23 March 2023
2022 has been a landmark year for the global gene therapy space. With August came the green light for bluebird bio’s Zynteglo in the US, the first FDA approval for a gene therapy in over three years. Hot off its heels we saw the accelerated approval